Ac Immune Sa · NASDAQ:ACIU
Ac Immune Sa — Shareholder Meeting (June 2022)
50 slides from Ac Immune Sa's shareholder meeting presentation, Jun 24, 2022
Slide 1: Pioneering Precision Medicine for Neurodegeneration
NASDAQ: ACIU | Annual General Meeting, June 2022 © 2022 AC Immune. Not to be used or reproduced without permission Pioneering Precision Medicine for Neurodegeneration NASDAQ: ACIU | Annual General Meeting, June 24, 2022 www.acimmune.com
Slide 2: Disclaimer
NASDAQ: ACIU | Annual General Meeting, June 2022 © 2022 AC Immune. Not to be used or reproduced without permission Disclaimer This presentation contains statements that constitute “forward - looking statements” within the meaning of Section 27 A of the Securities Act of 1933 and Section 21 E of the
Slide 3: Agenda
NASDAQ: ACIU | Annual General Meeting, June 2022 © 2022 AC Immune. Not to be used or reproduced without permission 3 Agenda 1. AC Immune’s leadership in neurodegenerative diseases 2. Achievements 2021/22 3. AC Immune’s business strategy 4. Pipeline update 5. Clinical - stage vaccine programs 6. Clin
Slide 4: 1. AC Immune's leadership in neurodegenerative diseases
1. AC Immune’s leadership in neurodegenerative diseases
Slide 5: What are we doing? Developing novel treatments and diagnostics
NASDAQ: ACIU | Annual General Meeting, June 2022 © 2022 AC Immune. Not to be used or reproduced without permission ■ First - in - class precision diagnostics to identify and analyze neurodegenerative diseases ■ Breakthrough therapeutic modalities to support treatment and prevention of neurodegenerat
Slide 6: Investment highlights
NASDAQ: ACIU | Annual General Meeting, June 2022 © 2022 AC Immune. Not to be used or reproduced without permission Investment highlights 6 Pioneering precision medicine for neurodegenerative diseases Broad, diversified pipeline in neurodegeneration Six Phase 2 programs; seven clinical readouts in 20
Slide 7: Neurodegenerative diseases represent a large and growing market
NASDAQ: ACIU | Annual General Meeting, June 2022 © 2022 AC Immune. Not to be used or reproduced without permission Neurodegenerative diseases represent a large and growing market Prevalence expected to increase drastically as the population ages 7 >50 Million people worldwide living with dementia 1
Slide 8: "Firsts" reflect ACIU's leadership in neurodegenerative disease
NASDAQ: ACIU | Annual General Meeting, June 2022 © 2022 AC Immune. Not to be used or reproduced without permission (1) Monoclonal antibody; (2) Alzheimer's disease; (3) alpha - synuclein; (4) Positron emission tomography; (5) TAR DNA binding pro tein - 43; (6) Small molecule Tau - specific aggregati
Slide 9: Misfolded proteins: Leading targets in neurodegenerative diseases
NASDAQ: ACIU | Annual General Meeting, June 2022 © 2022 AC Immune. Not to be used or reproduced without permission Misfolded proteins: Leading targets in neurodegenerative diseases 9 Abeta, Tau, a - synuclein, and TDP - 43 1 are important NDD 2 drug targets Soluble oligomers Misfolded protein Normal
Slide 10: Growth initiatives for 2022 and beyond
NASDAQ: ACIU | Annual General Meeting, June 2022 © 2022 AC Immune. Not to be used or reproduced without permission Growth initiatives for 2022 and beyond 10 G O A L S New areas Precision medicine Therapeutics Key NDD 1 targets: • Tau • Abeta • A - syn 2 Multiple modalities 4 partnerships Validated p
Slide 11: Successfully treating neurodegeneration requires precision medicine
NASDAQ: ACIU | Annual General Meeting, June 2022 © 2022 AC Immune. Not to be used or reproduced without permission Successfully treating neurodegeneration requires precision medicine 11 From a mono - to a multi - target combination approach Earlier, more reliable diagnosis may eventually lead to dis
Slide 12: 2. Achievements 2021/22
2. Achievements 2021/22
Slide 13: 2021 Highlights
NASDAQ: ACIU | Annual General Meeting, June 2022 © 2022 AC Immune. Not to be used or reproduced without permission AC Immune 2021 Highlights 13 Expanded Phase 1b/2a ACI - 35.030 trial to support advancement to late - stage development Promising data readouts from Phase 1b (DS 1 ) and Phase 2 (AD 2 )
Slide 14: 3. AC Immune's business strategy
3. AC Immune’s business strategy
Slide 15: Business strategy 2022
NASDAQ: ACIU | Annual General Meeting, June 2022 © 2022 AC Immune. Not to be used or reproduced without permission Business strategy 2022: further focus the execution strategy of 2021 Enhance value creation through acceleration of vaccine and PD 1 portfolio Precision medicine Alzheimer’s disease Par
Slide 16: SupraAntigen and Morphomer platforms
NASDAQ: ACIU | Annual General Meeting, June 2022 © 2022 AC Immune. Not to be used or reproduced without permission SupraAntigen ® and Morphomer ® platforms An integrated approach to Central Nervous System (CNS) - specific therapies 16 Clinically validated CNS - optimized Precision medicine enabling
Slide 17: 4. Pipeline update
4. Pipeline update
Slide 18: Broad and robust pipeline in neurodegenerative diseases
NASDAQ: ACIU | Annual General Meeting, June 2022 © 2022 AC Immune. Not to be used or reproduced without permission TARGET PRODUCT CANDIDATE INDICATION DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 PARTNER Tau ACI - 35.030 (anti - pTau vaccine ) AD 1 treatment Semorinemab (anti - Tau antibody) AD tre
Slide 19: Diversification into non-AD and non-CNS diseases
NASDAQ: ACIU | Annual General Meeting, June 2022 © 2022 AC Immune. Not to be used or reproduced without permission TARGET PRODUCT CANDIDATE INDICATION DISCOVERY PRECLINICAL PHASE 1 PHASE 2 a - synuclein (a - syn) Anti - a - syn antibody PD, NeuroOrphan Morphomer ® a - syn (a - syn inhibitor) PD, a -
Slide 20: 5. Clinical-stage vaccine programs
5. Clinical - stage vaccine programs
Slide 21: Proprietary SupraAntigen discovery platform
NASDAQ: ACIU | Annual General Meeting, June 2022 © 2022 AC Immune. Not to be used or reproduced without permission Proprietary SupraAntigen ® discovery platform Generation of vaccines and monoclonal antibodies 21 Target antigen SupraAntigen ® allows optimal configuration of liposomes for each applic
Slide 22: Disruptive potential of SupraAntigen-V
NASDAQ: ACIU | Annual General Meeting, June 2022 © 2022 AC Immune. Not to be used or reproduced without permission Disruptive potential of SupraAntigen ® - V Optimized vaccines delivering superior results in neurodegenerative diseases 22 (1) 100% response after 1 st injection; (2) Increases over tim
Slide 23: ACI-35.030: Anti-pTau vaccine being developed for AD
NASDAQ: ACIU | Annual General Meeting, June 2022 © 2022 AC Immune. Not to be used or reproduced without permission TARGET PRODUCT CANDIDATE INDICATION DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 PARTNER Tau ACI - 35.030 (anti - pTau vaccine ) AD treatment Semorinemab (anti - Tau antibody) AD treat
Slide 24: ACI-35.030 very encouraging interim Phase 1b/2a results in AD
NASDAQ: ACIU | Annual General Meeting, June 2022 © 2022 AC Immune. Not to be used or reproduced without permission ACI - 35.030 – very encouraging interim Phase 1b/2a results in AD 1 24 (1) Alzheimer’s disease; (2) Clinical Trials in Alzheimer’s Disease Conference; (3) Responders were defined as hig
Slide 25: ACI-35.030 generates a potent Ab response against pathological Tau
NASDAQ: ACIU | Annual General Meeting, June 2022 © 2022 AC Immune. Not to be used or reproduced without permission ACI - 35.030 generates a potent Ab 1 response against pathological Tau ACI - 35.030 generates excellent Ab responses against pTau 2 in an older population 25 (1) Antibody; (2) phosphory
Slide 26: ACI-7104: Anti-a-syn vaccine for Parkinson's disease
NASDAQ: ACIU | Annual General Meeting, June 2022 © 2022 AC Immune. Not to be used or reproduced without permission ACI - 7104: Anti - a - syn vaccine being developed for Parkinson's disease Phase 2 trial initiation expected in H2 26 (1) Alzheimer’s disease; (2) Open label extension study is ongoing;
Slide 27: Anti-a-syn vaccine is clinically validated in Parkinson's disease
NASDAQ: ACIU | Annual General Meeting, June 2022 © 2022 AC Immune. Not to be used or reproduced without permission Anti - a - syn 1 vaccine is clinically validated 2 in Parkinson’s disease Phase 1 results in The Lancet Neurology support best - in - class profile 27 (1) alpha - synuclein; (2) Volc et
Slide 28: ACI-7104: adaptive biomarker-based Phase 2 study in early PD
NASDAQ: ACIU | Annual General Meeting, June 2022 © 2022 AC Immune. Not to be used or reproduced without permission ACI - 7104: an adaptive biomarker - based Phase 2 study in early PD 1 Placebo - controlled Phase 2 Study Overview Dosing Schematic Part 1: Safety, Tolerability & Immunogenicity (1) Park
Slide 29: ACI-24: Vaccine targeting two pathological forms of Abeta
NASDAQ: ACIU | Annual General Meeting, June 2022 © 2022 AC Immune. Not to be used or reproduced without permission ACI - 24: Vaccine targeting two pathological forms of Abeta for AD 1 ACI - 24 targets pyroGlu - and oligomeric Abeta , which are believed to drive the progression of AD 29 (1) Alzheimer
Slide 30: Optimized anti-Abeta ACI-24: strong immune response against pyroglutamate Abeta
NASDAQ: ACIU | Annual General Meeting, June 2022 © 2022 AC Immune. Not to be used or reproduced without permission 30 (1) Pyroglutamate Cynomolgus serum – Day 120 Epitope mapping ■ Sustained and enhanced IgG response that binds Abeta(1 - 42) and pyroglutamate Abeta, the highly neurotoxic, truncated
Slide 31: ACI-24: Biomarker-based development in AD and AD in DS
NASDAQ: ACIU | Annual General Meeting, June 2022 © 2022 AC Immune. Not to be used or reproduced without permission 31 ACI - 24: Biomarker - based development in AD 1 and AD in DS 2 Placebo - controlled Phase 1b/2 Study Overview Trial Schematic (1) Alzheimer's disease; (2) Down syndrome - related AD;
Slide 32: 6. Clinical-stage monoclonal antibodies
6. Clinical - stage monoclonal antibodies
Slide 33: Semorinemab: Anti-Tau monoclonal antibody for AD
NASDAQ: ACIU | Annual General Meeting, June 2022 © 2022 AC Immune. Not to be used or reproduced without permission TARGET PRODUCT CANDIDATE INDICATION DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 PARTNER Tau ACI - 35.030 (anti - pTau vaccine ) AD treatment Semorinemab (anti - Tau antibody) AD treat
Slide 34: Lauriet study evaluating semorinemab in mild-to-moderate AD
NASDAQ: ACIU | Annual General Meeting, June 2022 © 2022 AC Immune. Not to be used or reproduced without permission Lauriet study evaluating the mAb 1 semorinemab in mild - to - moderate AD 2 One co - primary endpoint met: first positive cognitive results for an anti - Tau mAb therapy in AD 34 (1) Mo
Slide 35: Key findings from Phase 2 trials of semorinemab in AD
NASDAQ: ACIU | Annual General Meeting, June 2022 © 2022 AC Immune. Not to be used or reproduced without permission Key findings from Phase 2 trials of semorinemab in AD 1 Data provide further support for Tau as a target in AD 35 (1) Alzheimer‘s disease; (2) Plasma pharmacodynamics are similar betwee
Slide 36: Crenezumab: Monoclonal anti-Abeta antibody for AD
NASDAQ: ACIU | Annual General Meeting, June 2022 © 2022 AC Immune. Not to be used or reproduced without permission TARGET PRODUCT CANDIDATE INDICATION DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 PARTNER Tau ACI - 35.030 (anti - pTau vaccine ) AD 1 treatment Semorinemab (anti - Tau antibody) AD tre
Slide 37: API study design in Colombian familial AD population
NASDAQ: ACIU | Annual General Meeting, June 2022 © 2022 AC Immune. Not to be used or reproduced without permission Patient population ▪ Colombian family clan with Paisa mutation leading to Abeta accumulation and early onset AD 2 ▪ Largest autosomal - dominant AD cohort ▪ Nearly 100% certainty of dis
Slide 38: API study evaluating crenezumab in familial AD: primary endpoints
NASDAQ: ACIU | Annual General Meeting, June 2022 © 2022 AC Immune. Not to be used or reproduced without permission 38 API 1 study evaluating crenezumab in familial AD 2 : Primary Endpoints Numerical differences favoring crenezumab versus placebo were observed, but were not statistically significant
Slide 39: 7. First-in-class diagnostic for precision medicine
7. First - in - class diagnostic for precision medicine
Slide 40: ACI-12589: a-syn PET tracer
NASDAQ: ACIU | Annual General Meeting, June 2022 © 2022 AC Immune. Not to be used or reproduced without permission ACI - 12589: a - syn PET tracer Positive clinical proof - of - concept 40 (1) Alzheimer’s disease; (2) Open label extension study is ongoing; (3) Positron emission tomography; (4) Progr
Slide 41: ACI-12589 positive clinical proof-of-concept for a-syn PET tracer
NASDAQ: ACIU | Annual General Meeting, June 2022 © 2022 AC Immune. Not to be used or reproduced without permission ACI - 12589 - positive clinical proof - of - concept for an a - syn 1 - PET 2 tracer First - in - class diagnostic for MSA 3 and monitoring a - syn drug target engagement 41 (1) alpha -
Slide 42: 6. Near-term inflection points
6. Near - term inflection points
Slide 43: Clinical catalysts to drive further value creation
NASDAQ: ACIU | Annual General Meeting, June 2022 © 2022 AC Immune. Not to be used or reproduced without permission 2022 H1 H2 Tau ACI - 35.030 (anti - pTau vaccine) Phase 1b/2a interim analysis (highest dose) of ACI - 35.030 Decision to enter into late - stage development Semorinemab (anti - Tau ant
Slide 44: 7. Financial figures
7. Financial figures
Slide 45: Company and share facts
NASDAQ: ACIU | Annual General Meeting, June 2022 © 2022 AC Immune. Not to be used or reproduced without permission ■ Pioneering new ways to treat neurodegenerative diseases such as Alzheimer’s and Parkinson’s ■ Listed on Nasdaq since September 2016 (ticker: ACIU) ■ 83.5 million shares outstanding 1
Slide 46: External validation and cash generated by partnering deals
NASDAQ: ACIU | Annual General Meeting, June 2022 © 2022 AC Immune. Not to be used or reproduced without permission External validation and cash generated by 5 partnering 1 deals 46 Managing risk and retaining significant upside (1) Disclosure limited due to confidentiality agreements with collaborat
Slide 47: First Quarter 2022 financial update
NASDAQ: ACIU | Annual General Meeting, June 2022 © 2022 AC Immune. Not to be used or reproduced without permission 47 First Quarter 2022 financial update Strong cash position R&D expenses G&A expenses Other operating income ▪ CHF 173.8 million on March 31, 2022, compared to CHF 198.2 million on Dece
Slide 48: 8. Strategic Outlook
8. Strategic Outlook
Slide 49: Acceleration of value creation in 2022 and beyond
NASDAQ: ACIU | Annual General Meeting, June 2022 © 2022 AC Immune. Not to be used or reproduced without permission Acceleration of value creation in 2022 and beyond 49 (1) Alzheimer’s disease Leading with Science Precision Medicine Enabling Platforms Execution Strategy Financial Strength First - or
Slide 50: AC Immune: pioneering science and precision medicine
NASDAQ: ACIU | Annual General Meeting, June 2022 © 2022 AC Immune. Not to be used or reproduced without permission 50 AC Immune: pioneering science and precision medicine By pairing cutting - edge diagnostics with highly selective therapeutic agents, we aim to shift the treatment paradigm of neurode